TNFRSF17 and plasma cell myeloma: Regarding the antigens of the commercialised antitumour CAR-T therapies, idecabtagene vicleucel and ciltacabtagene autoleucel are directed against the B cell maturation antigen (BCMA), which overexpression and activation is associated to multiple myeloma, while all the others are designed to target CD19, a marker of B cells.